Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $51.30 USD
Change Today -0.44 / -0.85%
Volume 4.8M
MYL On Other Exchanges
As of 8:10 PM 11/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Albany Gate

Darkes Lane

Potters Bar, EN6 1AG

United Kingdom

Phone: 44 1707 853000

Fax: 44 1707 643148

rotecting Perforomist Inhalation Solution. In addition to EpiPen Auto-Injector and Perforomist Inhalation Solution, Mylan Specialty also markets ULTIVA, which is an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures and is generally administered by an infusion device. Customers and Marketing Generics Segment In North America, the company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. The company also markets its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. These customers, called indirect customers, purchase its products primarily through its wholesale customers. In Europe and Rest of World, generic pharmaceuticals are sold to wholesalers, independent pharmacies and, in certain countries, directly to hospitals. The company’s API are sold primarily to generic FDF manufacturers throughout the world, as well as to other subsidiaries. Specialty Segment Mylan Specialty markets its products to various different customer audiences in the U.S., including health care practitioners, wholesalers, pharmacists and pharmacy chains, hospitals, payers, pharmacy benefit manager, health maintenance organizations, home health care, long-term care, and patients. Major Customers During 2014, the company’s customers included McKesson Corporation; AmeriSourceBergen Corporation; and Cardinal Health, Inc. Seasonality Certain parts of the company’s business are affected by seasonality, primarily the Specialty segment and Rest of World within its Generics segment. Research and Development For the year ended December 31, 2014, the company’s research and development spending was $582 million. Government Regulations In Japan, the company is governed by various laws and regulations, including the Pharmaceutical Affairs Law (Law No. 145, 1960), as amended by the Pharmaceuticals and Medical Devices Law (PMDL), and the Products Liability Law (Law No. 85, 1994). Under the amended PMDL, the retailing or supply of a pharmaceutical that a person has manufactured (including manufacturing under license) or imported is defined as marketing, and in order to market pharmaceuticals, one has to obtain a license, which the company refers to herein as a Marketing License, from the Minister of the Ministry of Health, Labor and Welfare. History Mylan N.V. was founded in 1961.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $51.30 USD -0.44

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,750 JPY +16.00
Becton Dickinson and Co $150.25 USD -1.04
Perrigo Co PLC $149.39 USD -1.10
Valeant Pharmaceuticals International Inc C$121.18 CAD +0.83
WW Grainger Inc $200.54 USD +0.89
View Industry Companies

Industry Analysis


Industry Average

Valuation MYL Industry Range
Price/Earnings 28.9x
Price/Sales 2.8x
Price/Book 2.6x
Price/Cash Flow 30.2x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MYLAN NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at